Magainin Pharmaceuticals Inc. of Plymouth Meeting, Pa., saidThursday it is beginning Phase I clinicals for its broad-spectrum topical anti-bacterial and anti-fungal drug, MSI-78.Preclinical tests showed the drug to be effective against abroad spectrum of bacteria and fungi associated with skininfections, the company said.

(c) 1997 American Health Consultants. All rights reserved.

No Comments